Skip to main content

This job has expired

You will need to login before you can apply for a job.

Director, Regulatory Genomics

Employer
Intellia Therapeutics
Location
Cambridge, MA
Start date
Apr 6, 2024

View more

Job Details

Why Join Intellia?

Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done.

We wantall ofour people to go beyond what is possible. We aren’t constrained by typical end rails, and we aren’t out to just “treat” people. We’re all in this for something more. We’re driven to cure and motivated for change. Just imagine the possibilities of what we can do together.

How you will Achieve More with Intellia:

Intellia is look for a Director, Genotoxicity Regulatory Lead to support the advancement of genome editing products into the clinic. Within this leadership role, you will support the in vivo and cell therapy development programs in genotoxicity strategy and implementation. This is a highly visible leadership position serving on multiple therapeutic program teams supporting regulatory filings and documentation, as well as interacting with health authorities. In this role you will:

  • Serve as SME for genotoxicity assessment in support of in vivo and cell therapy development program advancement to the clinic

  • Effectively interact with other functional area experts in a program team environment to develop overall genotoxicity assessment strategy and defend those recommendations to internal governance committees

  • Partner with toxicology on strategy and guidance for genetic safety assessment for gene editing approaches

  • Work closely with Genomic Innovation to align on genotox testing strategy for research programs headed to development candidate nomination

  • Stay current on regulatory requirements for genome editing therapies and assess new technologies

  • Work closely with NGS production, Quality and PreClinical Genotox for compliant execution of genotoxicity data packages in support of regulatory filings and clinical programs

  • Partner with computational biology and software engineering on effective approaches for data capture, structuring, analysis and delivery

  • Partner with regulatory, clinical, and program team leads to support regulatory filings

  • Interact with Health Authorities, in writing and verbally, including pre-submission (e.g., pre-IND), scientific advice filings, IND or CTA, meeting briefing books, or other requests from global regulatory authorities

  • Serve as external SME for genotoxicity assessment for CRISPR based products presenting at conferences, interacting with pre-competitive consortia, and supporting and writing manuscripts focused on genotoxicity methods and justification

About You:

The Director, Regulatory Genomics will have demonstrated expertise in regulatory writing and strategy as well as health authority interactions both written and verbal with a focus on genomics and genotoxicity evaluation. Experience in supporting gene editing therapies into the clinic with a focus on genotoxicity is required. Additionally, experience with toxicology, NGS, sequencing methodologies, molecular biology, and gene editing approaches is preferred.

  • PhD with 10 years directly related industry experience.

  • Experience in writing and documentation to support regulatory filings as well as response to health authority questions and interacting with health authorities.

Meet your future team:

You will be an SME for genotoxicity and gene editing products working closely with Computational Biology, Toxicology, Genomics Innovation and PreClinical Genotox to support the development of genome editing based therapeutics into the clinic. We are accountable for enabling our programs in early research to reach development candidate nomination through regulatory filing and into clinical trials.

In this key leadership role, you will report directly to the Vice President, Genomic Operations who instills a culture of teamwork, respect, inclusion, collaboration, and communication ensuring that each team member strives to reach their professional and personal potential.

#LI-KO2

Covid-19 Vaccination Policy:All Intellia employees, regardless of work location, are expected to follow all applicable federal, state, and local public health regulations and guidelines, and are strongly encouraged to follow all public health recommendations, including being vaccinated for COVID-19.

EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.

Company

Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
 
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
 
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

Stock Symbol: NTLA

TwitterInstagram

Company info
Website
Phone
(857) 285-6200
Location
40 Erie Street
Cambridge
Massachusetts
02139
US

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert